GlassScriptPhysician profile
Ramesh Khanna
NPI 1457300287
$13,817.25
in general payments reported to CMS, 2019-2025
19 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $103 · 2022: $1,813 · 2023: $11K · 2024: $447 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $903 · Travel and Lodging: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,479.38 |
| Food and Beverage | $902.95 |
| Travel and Lodging | $231.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $12,538.75 | 2019-2023 | Renal - Pd |
| Travere Therapeutics, INC. | $325.57 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $159.64 | 2019-2025 | Jynarque |
| Amgen INC. | $152.58 | 2019-2025 | Tavneos |
| Vifor Pharma, INC. | $87.11 | 2019-2025 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $82.01 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $81.03 | 2024-2025 | |
| Horizon Therapeutics Plc | $59.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $59.17 | 2020-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $55.94 | 2019 | |
| Genzyme Corporation | $44.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $31.48 | 2025 | Prevymis |
| Mozarc Medical US LLC | $22.94 | 2025 | Palindrome |
| Biobeat USA INC. | $22.05 | 2024 | Bb-613 Bpm Kit |
| Bayer Healthcare Pharmaceuticals INC. | $21.24 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $20.99 | 2025 | Renal - Pd |
| Glaxosmithkline, LLC. | $20.59 | 2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $16.17 | 2025 | Terlivaz |
| Rockwell Medical, INC. | $15.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Khanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.